目的 探讨羧甲司坦联合丙卡特罗治疗小儿支气管哮喘的临床疗效。方法 选取2021年6月-2023年7月天津市人民医院儿科收治的80例支气管哮喘患儿,按照治疗方式的不同分对照组和治疗组,每组各40例。对照组患儿口服盐酸丙卡特罗口服溶液,3 mL/次,1次/d。治疗组在对照组的治疗基础上口服羧甲司坦片,0.5片/次,3次/d。两组均连续治疗7 d。观察两组的临床疗效和症状消失时间,比较治疗前后儿童哮喘控制测试(C-ACT)评分、血清炎性因子水平。结果 治疗后,治疗组总有效率是95.08%,显著高于对照组的77.50%(P<0.05)。治疗后,治疗组哮鸣音消失、痰鸣音消失、咳嗽消失、喘息消失时间均显著短于对照组(P<0.05)。治疗后,两组患者C-ACT评分均显著高于同组治疗前(P<0.05);且治疗后,治疗组C-ACT评分显著高于对照组(P<0.05)。治疗后,两组干扰素-γ(INF-γ)水平较治疗前显著升高,而白细胞介素-6(IL-6)、细胞间黏附因子-1(ICAM-1)、白三烯B4(LTB4)水平显著降低(P<0.05);且治疗后,治疗组血清学指标改善优于对照组(P<0.05)。结论 羧甲司坦联合丙卡特罗治疗小儿支气管哮喘具有较好的临床疗效,可有效改善患儿临床症状,调节患儿机体血清炎性因子,且安全有效,值得临床借鉴应用

ObjectiveTo explore the clinical effect of carbocisteine combined with procaterol in treatment of bronchial asthma in children. Methods A total of 80 children with bronchial asthma admitted to the Department of Pediatrics of Tianjin Union Medical Center from June 2021 to July 2023 were selected and divided into control group and treatment group according to different treatment methods, with 40 cases in each group. Patients in the control group were po administered with Procaterol Hydrochloride Oral Solution, 3 mL/time, once daily. Patients in the treatment group were po administered with Carbocisteine Tablets on the basis of the control group, 0.5 tablet/time, three times daily. Both groups were treated continuously for 7 d. The clinical efficacy and symptom resolution time of two groups were observed, and the scores of childhood Asthma Control test (C-ACT) and serum inflammatory factors before and after treatment were compared. Results After treatment, the total effective rate of the treatment group was 95.08%, which was significantly higher than that of control group (77.50%, P < 0.05). After treatment, the disappearance time of wheezing, phlegm chirping, cough, and wheezing in treatment group was significantly shorter than that in control group (P < 0.05). After treatment, C-ACT scores in 2 groups were significantly higher than before treatment (P < 0.05). After treatment, the C-ACT score of treatment group was significantly higher than that of control group (P < 0.05). After treatment, the levels of interferon-γ (INF-γ) in two groups were significantly higher than before treatment, but the levels of interleukin-6 (IL-6), intercellular adhesion factor-1 (ICAM-1), and leukotriene B4 (LTB4) were significantly decreased (P < 0.05). After treatment, serological indexes in treatment group were better than those in control group (P < 0.05). Conclusion Carbocisteine combined with procaterol has good clinical efficacy in treatment of bronchial asthma in children, and can effectively improve the clinical symptoms of children, regulate the serum inflammatory factors with good safety and effect, which is worthy of clinical application.

R974

天津市人民医院科研项目（2016Y52D004）